In a clinical trial, Altimmune demonstrated promising results in mitigating muscle loss with a weight loss drug, potentially distinguishing it from competitors.

Quick Summary:

The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that they shrink critical muscle mass.

Those results suggest a higher rate of lean mass decline than in Altimmune's trial.

Those results are similar to those often seen with diet and exercise programs for weight loss.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: EconomyBusiness

Markets: United States

Topics: Altimmune Inc Pharmaceuticals US: News Novo Nordisk A/S Biotech and Pharmaceuticals Science Biotechnology Business Cnbc Source:tagname:CNBC US Source Companies Eli Lilly and Co Health care industry Articles Business News

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-03-27 @ 18:30:36 (1 months ago)

News Timezone: GMT -5:00

News Source URL: cnbc.com

Language: English

Article Length: 541 words

Reading Time: 4 minutes read

Sentences: 20 lines

Sentence Length: 28 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © CNBC

News ID: 20538779

View Article Analysis

About CNBC

Main Topics: EconomyBusiness

Official Website: cnbc.com

Year Established: 2005

Headquarters: United States

News Last Updated: 1 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT -5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #5

Publisher Details

Frequently Asked Questions